Alcon Inc. (ALC)
| Market Cap | 38.46B |
| Revenue (ttm) | 10.03B |
| Net Income (ttm) | 1.07B |
| Shares Out | 494.40M |
| EPS (ttm) | 2.16 |
| PE Ratio | 35.85 |
| Forward PE | 23.66 |
| Dividend | $0.22 (0.28%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 1,407,747 |
| Open | 77.81 |
| Previous Close | 77.41 |
| Day's Range | 77.39 - 78.07 |
| 52-Week Range | 77.36 - 100.71 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 96.73 (+24.59%) |
| Earnings Date | Nov 11, 2025 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $96.73, which is an increase of 24.59% from the latest price.
News
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS.
Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss
LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on patients with dry age-related macular degeneration.
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breac...
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025.
Alcon to Present at 2025 Baird Global Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference.
Trouble Ahead for Alcon Shares
Alcon Inc. is showing clear signs of weakness on its weekly chart. The stock has entered Phase 8 of its 18-phase Adhishthana cycle, and a critical breakdown from its Cakra formation has triggered what...
These Analysts Slash Their Forecasts On Alcon After Q2 Earnings
Alcon Inc ALC posted better-than-expected earnings for the second quarter and cut its 2025 outlook late on Tuesday, citing increased tariff impact.
Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Call Participants Daniel Cravens - Vice President of Investor Relations David J. Endicott - CEO & Director Timothy C.
Alcon: More Than Meets The Eye
Alcon remains a leader in eye care, benefiting from strong market positioning and long-term industry tailwinds like aging populations and technological advances. Recent M&A activity, including the STA...
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday.
Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit
The company said it expects a $100 million hit from tariffs this year.
Alcon shares fall after it cuts guidance and warns of tariff impact
Shares in Alcon fell as much as 11.6% on Wednesday after the Swiss-American eye care group cut its 2025 sales outlook late on Tuesday flagging the impact of U.S. tariffs.
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
GENEVA--(BUSINESS WIRE)--Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical.
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
AHMEDABAD, India--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract ...
STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company - STAA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of STAAR...
Alcon Agrees to Acquire STAAR Surgical
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon Agrees to Acquire STAAR Surgical.
Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received ...
Alcon Canada Earns Global Recognition as a Top Employer
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Can...
Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System
Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification...
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intrao...
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...
US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand f...